leisure time -WSS

leisure time

author：explore 2025-10-01 11:34:57 - browse：5189

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

explore

WSS

Teach medical students about patients with intellectual disabilities

Analysis of telehealth claims data suggest service duplication

Chemotherapy shortages won’t get better under Biden’s latest plan

FDA needs staff influx to meet gene therapy needs, Marks says

Physician executives need more than on

Patients' immediate access to test results puts radiologists in a bind

focus

leisure time

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Was Amgen transparent enough on FDA's concern on cancer drug?

Novavax promises a turnaround & Lilly roils the obesity market

A virus, fished out of a lake, may have saved a man’s life

Activists slam private health insurers over coverage restrictions

CMS should re

Bright Health sells Medicare Advantage business to Molina

Teach medical students about patients with intellectual disabilities

Duchenne breakthrough therapy leaves behind pioneering families

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

entertainment

Leukemia patients are helped by Syndax's new type of therapy

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Why Charlie Gard's case is so disturbing to Americans

Bill would stop addiction treatment from triggering child abuse inquiry

A Q&A with the global head of Boehringer Ingelheim's innovation unit

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Wikipedia

Wikipedia

explore

entertainment